New and emerging pharmacotherapeutic approaches for insomnia

Research output: Contribution to journalArticle

Abstract

Advances in understanding the neurochemistry of sleep and waking have stimulated new pharmacological directions in the treatment of insomnia. While the sedation of historic insomnia medications was discovered serendipitously, now compounds can be developed for specific molecular targets with known sleep-related actions. Numerous investigational compounds, including some entirely novel approaches, are being evaluated currently as possible insomnia treatments. In recent years the US Federal Drug Administration (FDA) has approved medications with new pharmacodynamic and pharmacokinetic properties thereby extending the options for personalized pharmacotherapy. The FDA is reviewing new applications for innovative sleep-promoting medications currently, including suvorexant and tasimelteon. Presently the FDA-approved insomnia treatment medications include benzodiazepine receptor agonists available in immediate-release, extended-release, and alternative delivery oral absorption formulations; a melatonin receptor agonist; and a histamine receptor antagonist. Clinical indications include insomnia associated with difficulty with sleep onset, sleep maintenance, and middle-of-the-night awakenings. Alternative approaches to treating insomnia have included prescription medications employed on an off-label basis for insomnia, over-the-counter sleep aids, and assorted unregulated substances marketed to enhance sleep.

Original languageEnglish (US)
Pages (from-to)214-224
Number of pages11
JournalInternational Review of Psychiatry
Volume26
Issue number2
DOIs
StatePublished - 2014

Fingerprint

Sleep Initiation and Maintenance Disorders
Sleep
Pharmaceutical Preparations
Melatonin Receptors
Neurochemistry
Histamine Receptors
Histamine Antagonists
GABA-A Receptors
Prescriptions
Therapeutics
Pharmacokinetics
Maintenance
Pharmacology
Drug Therapy

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Medicine(all)

Cite this

New and emerging pharmacotherapeutic approaches for insomnia. / Neubauer, David.

In: International Review of Psychiatry, Vol. 26, No. 2, 2014, p. 214-224.

Research output: Contribution to journalArticle

@article{9fe2e2283d234e059ed932c004a0f5da,
title = "New and emerging pharmacotherapeutic approaches for insomnia",
abstract = "Advances in understanding the neurochemistry of sleep and waking have stimulated new pharmacological directions in the treatment of insomnia. While the sedation of historic insomnia medications was discovered serendipitously, now compounds can be developed for specific molecular targets with known sleep-related actions. Numerous investigational compounds, including some entirely novel approaches, are being evaluated currently as possible insomnia treatments. In recent years the US Federal Drug Administration (FDA) has approved medications with new pharmacodynamic and pharmacokinetic properties thereby extending the options for personalized pharmacotherapy. The FDA is reviewing new applications for innovative sleep-promoting medications currently, including suvorexant and tasimelteon. Presently the FDA-approved insomnia treatment medications include benzodiazepine receptor agonists available in immediate-release, extended-release, and alternative delivery oral absorption formulations; a melatonin receptor agonist; and a histamine receptor antagonist. Clinical indications include insomnia associated with difficulty with sleep onset, sleep maintenance, and middle-of-the-night awakenings. Alternative approaches to treating insomnia have included prescription medications employed on an off-label basis for insomnia, over-the-counter sleep aids, and assorted unregulated substances marketed to enhance sleep.",
author = "David Neubauer",
year = "2014",
doi = "10.3109/09540261.2014.888990",
language = "English (US)",
volume = "26",
pages = "214--224",
journal = "International Review of Psychiatry",
issn = "0954-0261",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - New and emerging pharmacotherapeutic approaches for insomnia

AU - Neubauer, David

PY - 2014

Y1 - 2014

N2 - Advances in understanding the neurochemistry of sleep and waking have stimulated new pharmacological directions in the treatment of insomnia. While the sedation of historic insomnia medications was discovered serendipitously, now compounds can be developed for specific molecular targets with known sleep-related actions. Numerous investigational compounds, including some entirely novel approaches, are being evaluated currently as possible insomnia treatments. In recent years the US Federal Drug Administration (FDA) has approved medications with new pharmacodynamic and pharmacokinetic properties thereby extending the options for personalized pharmacotherapy. The FDA is reviewing new applications for innovative sleep-promoting medications currently, including suvorexant and tasimelteon. Presently the FDA-approved insomnia treatment medications include benzodiazepine receptor agonists available in immediate-release, extended-release, and alternative delivery oral absorption formulations; a melatonin receptor agonist; and a histamine receptor antagonist. Clinical indications include insomnia associated with difficulty with sleep onset, sleep maintenance, and middle-of-the-night awakenings. Alternative approaches to treating insomnia have included prescription medications employed on an off-label basis for insomnia, over-the-counter sleep aids, and assorted unregulated substances marketed to enhance sleep.

AB - Advances in understanding the neurochemistry of sleep and waking have stimulated new pharmacological directions in the treatment of insomnia. While the sedation of historic insomnia medications was discovered serendipitously, now compounds can be developed for specific molecular targets with known sleep-related actions. Numerous investigational compounds, including some entirely novel approaches, are being evaluated currently as possible insomnia treatments. In recent years the US Federal Drug Administration (FDA) has approved medications with new pharmacodynamic and pharmacokinetic properties thereby extending the options for personalized pharmacotherapy. The FDA is reviewing new applications for innovative sleep-promoting medications currently, including suvorexant and tasimelteon. Presently the FDA-approved insomnia treatment medications include benzodiazepine receptor agonists available in immediate-release, extended-release, and alternative delivery oral absorption formulations; a melatonin receptor agonist; and a histamine receptor antagonist. Clinical indications include insomnia associated with difficulty with sleep onset, sleep maintenance, and middle-of-the-night awakenings. Alternative approaches to treating insomnia have included prescription medications employed on an off-label basis for insomnia, over-the-counter sleep aids, and assorted unregulated substances marketed to enhance sleep.

UR - http://www.scopus.com/inward/record.url?scp=84901823171&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901823171&partnerID=8YFLogxK

U2 - 10.3109/09540261.2014.888990

DO - 10.3109/09540261.2014.888990

M3 - Article

C2 - 24892896

AN - SCOPUS:84901823171

VL - 26

SP - 214

EP - 224

JO - International Review of Psychiatry

JF - International Review of Psychiatry

SN - 0954-0261

IS - 2

ER -